Target intelligence / Profile preview

Plasmodium falciparum DNA damage-inducible 1 protein (retroviral aspartyl protease) (PfDDI1)

Target
PfDDI1
Molecular classification
Enzyme (specifically an aspartyl protease), Retroviral protease-like protein (RVP domain-containing), Ubiquitin-proteasome system component (contains UBL domain)
01

Overview

Plasmodium falciparum DNA damage-inducible 1 protein (PfDDI1) is an essential aspartyl protease featuring a retroviral protease (RVP) domain and a ubiquitin-like (UBL) domain. It performs critical roles in the ubiquitin-proteasome system for protein degradation, removal of DNA-protein crosslinks, and maintaining parasite survival during all life stages. PfDDI1 depletion results in the accumulation of DNA-protein crosslinks, increased sensitivity to DNA-damaging agents and antimalarials, and impaired parasite growth, supporting its status as a validated therapeutic target. Its retroviral protease domain makes it susceptible to inhibition by HIV protease inhibitors (e.g., lopinavir), as well as artemisinin, which bind directly to the catalytic motif of PfDDI1. Knockdown of PfDDI1 not only impairs parasite survival but also confers immunity in murine models, highlighting its potential utility in vaccine development.

Other names
DNA damage-inducible 1 proteinPfDdi1Ddi1 retroviral proteaseRetropepsin-like protease
02

Mechanism of action

Inhibition by retroviral protease inhibitors (e.g., lopinavir) reduces parasite fitness and growth. Artemisinin binds directly to the conserved aspartic protease motif in PfDdi1, inhibiting its function and leading to parasite death. Knockdown or inhibition increases parasite sensitivity to DNA damage.

03

Biological functions

Proteasomal degradation of specific proteinsRemoval of DNA-protein crosslinks (DPCs)Chromatin associationProtein ubiquitylation and homeostasisSurvival and development of malaria parasite across all life cycle stages
04

Disease associations

Infection: essential for malaria parasite survival, making it a target for malaria therapyPotential vaccine target due to immunity conferred by knock-down parasites
05

Safety considerations

No specific safety concerns reported for targeting PfDDI1 directly, but general challenges include drug resistance and potential toxicity if off-target effects occur, as Ddi1 is involved in essential cellular processes
06

Interacting drugs

Lopinavir (HIV protease inhibitor)

1 more in the full profile.

07

Biomarkers

Expression or depletion of PfDDI1 may signal DPC accumulation or altered sensitivity to antimalarial therapy; however, established clinical biomarkers are currently lacking

Beyond the preview

Go deeper on Plasmodium falciparum DNA damage-inducible 1 protein (retroviral aspartyl protease) (PfDDI1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmodium falciparum DNA damage-inducible 1 protein (retroviral aspartyl protease) (PfDDI1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call